Keyword: Edwards Lifesciences
The FDA broadened its approvals of several transcatheter aortic valve replacements to include patients at a low risk of surgical complications.
Edwards Lifesciences and Johnson & Johnson Vision Care have made multimillion-euro investments to boost their manufacturing capacity in Ireland.
A study of 100 physicians who received payments from device makers declared their conflict of interest in journal articles only 37% of the time.
The agreement sees Boston Scientific buy $90 million of Millipede stock and gain the right to acquire the rest of the business for up to $450 million.
The takeover gives Edwards control of a technology to repair the hearts of patients with the degenerative form of mitral valve disease.
Medtronic has posted a look at data on the first 50 patients treated with its transcatheter mitral valve replacement (TMVR) system.
Boston Scientific started 2016 strong thanks to double-digit growth in four businesses: Endoscopy, Urology and Pelvic Health, Interventional Cardiology and Peripheral Intervention. In June, it announced a global restructuring program to support long-term objectives.
Edwards Lifesciences has earned FDA clearance for its blood flow monitoring platform.
Following a U.K. court's mixed decision, a German court found Edwards infringed two Boston Scientific patents, while Boston Sci violated one Edwards patent.
After months of patent squabbling between Boston Scientific and Edwards, a U.K. court has deemed one of Boston Sci’s heart valve patents invalid.